Table 2.
Clinical characteristics related to Clostridioides difficile infection by tumor type
| Characteristic | Solid tumor group (n = 12) | Hematologic malignancy group (n = 7) |
|---|---|---|
| PPI use <3 months before FMT, no. (%) | 9 (75%) | 5 (71%) |
| Antibiotic usea <3 months before FMT, no. (%) | 9 (75%) | 6 (86%) |
| Antibiotic use at the time of FMT, no. (%) | 4 (33%) | 0 |
| Cancer treatment <6 months before FMT, no. (%) | 10 (83%) | 6 (86%) |
| Immunosuppressant use <3 months before FMT, no. (%) | 3 (25%) | 4 (57%) |
| Peak frequency of stools /day before FMT, median (IQR) | 10 (6-15) | 10 (10-20) |
| Median WBC nadir before FMT (K/µL), (IQR) (n = 18) | 5.7 (3.6-6.1) | 4.9 (3.5-5.5) |
| Neutropenia (ANC<1000 cells/µL), no. (%) | 0 | 0 |
| Median nadir albumin <2 weeks before FMT, (IQR) (n = 14) | 3.8 (3.0-4.1) | 3.7 (3.3-3.9) |
| Median peak creatinine <2 weeks of FMT, (IQR) (n = 16) | 1.0 (0.7-1.2) | 1.1 (0.8-1.3) |
| Episodes of CDI/case <1 year before FMT, mean (SD) | 2 (1) | 3 (1) |
| Courses of CDI antibiotic treatment/case <1 year of FMT, mean (SD) | 3 (1) | 4 (2) |
| Hospitalization/emergency room requirement related to CDI, no. (%) | 7 (58%) | 4 (57%) |
| Hospitalizations/case <12 months before FMT, mean (SD) | 1.3 (1) | 1.6 (2) |
| Total treatments for all CDI episodes together, no. | ||
| Metronidazole monotherapy | 0 | 0 |
| Vancomycin monotherapy | 0 | 3 |
| Fidaxomicin monotherapy | 0 | 0 |
| Combination | 11 | 8 |
| Bezlotoxumabb | 3 | 1 |
| Most recent pre-transplant CDI vancomycin treatment, no. (n = 19) | ||
| Vancomycin taper and pulse | 2 | 0 |
| Vancomycin taper, pulse and maintenance | 1 | 2 |
| Vancomycin 10-day course and maintenance | 6 | 4 |
| No maintenance antibiotics for CDI | 3 | 1 |
ANC, absolute neutrophil count; CDI, Clostridioides difficile infection; IQR, interquartile range; PPI, proton pump inhibitor; SD, standard deviation; WBC, white blood cell count.
a Indications treated with antibiotics included urinary tract infection, cellulitis, diverticulitis, abscess, pneumonia, fever, diarrhea/CDI, prophylaxis, empirical coverage.
b Bezlotoxumab was always used as a part of combination treatment.